Risk factors

Polaryx Therapeutics (PLYX) risk factors

Item 1A of every Polaryx Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open PLYX in Gloomberb →
  • FY2025 10-K risk factors

    63 risks. Clinical stage biotech with accumulated deficit of $99.6 million dependent on PLX-200 and PLX-300. Programs focus on rare pediatric lysosomal storage disorders facing intense competition. Substantial doubt about ability to continue as a going concern.

    Filed Mar 24, 2026